Company intelligence / Profile preview

Amadix

Valladolid, Castile and León, Spainamadix.com ↗

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Amadix has commercialized PreveCol®, a CE-marked blood test for early detection of colorectal cancer and advanced adenomas in Europe. The company’s pipeline includes two additional blood-based diagnostic tests—DiagnoLung and PancreaDix—for early lung and pancreatic cancer detection, both currently in clinical validation. The company recently secured €15 million from the European Investment Bank to support further development, international expansion, U.S. clinical trials of PreveCol, and manufacturing scale-up.

Therapeutic areas: Oncology
Modalities: Diagnostic test (blood-based)BiomarkersMachine learning algorithm (for diagnostics)Liquid biopsy
Industry: Molecular Diagnostics

Partnerships

Network of over forty pharmaceutical/diagnostic companies following projects under confidentiality agreements

Beyond the preview

Go deeper on Amadix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amadix.

Explore the full profile